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ABSTRACT
To reduce the in-vivo toxicity of the broad-spectrum antifungal drug amphotericin B, various lipid
formulations of amphotericin B, ranging from lipid complexes to small unilamellar liposomes, have
been developed and subsequently commercialised. These structurally diverse formulations differ in
their serum pharmacokinetics as well as their tissue localisation, tissue retention and toxicity. These
differences can affect the choice of formulation for a given infection, the time of initiation of treatment,
and the dosing regimen. Although preclinical studies have shown similarities in the in-vitro and in-vivo
antifungal activity of the formulations with comparable dosing, their acute and chronic toxicity profiles
are not the same, and this has a significant impact on their therapeutic indices, especially in high-risk,
immunosuppressed patients. With the recent introduction of new antifungal drugs to treat the
increasing numbers of infected patients, the amphotericin B lipid formulations are now being studied to
evaluate their potential in combination drug regimens. With proven efficacy demonstrated during the
past decade, it is expected that amphotericin B lipid formulations will remain an important part of
antifungal drug therapy.
Keywords Amphotericin B, combination antifungal therapy, drug delivery, drug toxicity, preclinical
studies, review, tissue localisation
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INTRODUCTION
Despite the advent of newer antifungal agents,
amphotericin B (AMB) has remained the drug of
choice for many life-threatening invasive fungal
infections. Some of the reasons for this are that
AMB is a drug with one of the broadest spectra of
activity, and few instances of drug resistance have
been reported after 60 years of use [1]. Lipid
formulations of AMB have been shown to reduce
the parent drug nephrotoxicity while retaining
the drug’s activity, providing a better therapeutic
index for the drug.
In many countries, three lipid formulations of
AMB are available: AmBisome (AmBi, liposo-
mal amphotericin B; Gilead Sciences Inc., Foster
City, CA, USA), Abelcet (ABLC, amphotericin B
lipid complex; Enzon Pharmaceuticals Inc.,
Bridgewater, NJ, USA; Cephalon Limited, Wel-
win Garden City, UK), and Amphocil ⁄Ampho-
tec (ABCD, amphotericin B colloidal dispersion;
Three River Pharmaceuticals Inc., Cranberry
Township, PA, USA). Although all these formu-
lations contain AMB, they differ with regard to
their lipid composition, shape, size, stability,
pharmacokinetics and toxicity. These properties
may in turn influence therapeutic use of the
various formulations. Although there are other
AMB lipid products available in certain parts of
the world, e.g., FungisomeTM in India [2], NS-718
in Japan [3] and Anfogen in Argentina [4], this
review will focus on the differences in the more
widely commercialised formulations (Table 1).
BASIC CHARACTERISTICS
Structure
AmBi consists of spherical unilamellar liposomes
with a mean diameter of <100 nm, composed of
hydrogenated soy phosphatidylcholine, choles-
terol, distearoyl-phophatidylglycerol and AMB
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Table 1. Similarities and differences between AmBisome (AmBi) and Abelcet (ABLC)
Characteristic AmBisome Abelcet References
Structure Spherical liposomes,
<100 nm
Ribbon-like complexes,
1.6–11 lm
[5,7]
Pharmacokinetics Cmax = 83.0 mg ⁄L Cmax = 1.7 mg ⁄L [9–13]
AUC = 555 mg ⁄L AUC = 14 mg ⁄L
Vd = 0.11 L ⁄ kgÆh ⁄mL Vd = 131 L ⁄ kgÆh ⁄mL
Cl = 11 mg ⁄L ⁄h ⁄ kg Cl = 436 mg ⁄L ⁄h ⁄ kg
Toxicity Murine LD50 ‡ 175 mg ⁄ kg Murine LD50 > 40 mg ⁄kg [8,14,17,21,22]
Multiple dosing in rats: Multiple dosing in rats:
20 mg ⁄ kg = minimal
nephrotoxicity
10 mg ⁄kg = mild
nephrotoxicity
Mode of action Liposome targeting to
fungal cell wall with
release of AMB into
fungus
Release of AMB from
complexes, possibly host
macrophage- and
phospholipase-mediated
[26–29]
In-vivo efficacy
Lung infections Efficacy at 5–30 mg ⁄ kg
dosing
Efficacy at 5–12.8 mg ⁄ kg,
with nephrotoxicty at
15 mg ⁄ kg dosing
[30–36]
Brain infections Efficacy at 5–30 mg ⁄ kg
dosing
Efficacy at 5–15 mg ⁄ kg
dosing
[39–44]
Kidney, liver,
spleen infections
Efficacy at 3–50 mg ⁄ kg
dosing depending on
type of infection
Efficacy at 5–15 mg ⁄ kg
dosing depending on
type of infection
[45–52]
Effect of drug concentration
and localisation on
therapeutic efficacy
Comparable efficacy to
ABLC even with lower
AmBi tissue concentrations
Higher concentrations in
lung, liver and spleen as
compared to AmBi
[32,55,56]
Targeting of liposomes to
fungal infection sites in
tissues as well as uptake
by macrophages
Uptake by macrophages [28]
Toxicity and efficacy
Lung infections Efficacy without
nephrotoxicity at
5–20 mg ⁄ kg
Efficacy without
nephrotoxicity at 5 mg ⁄ kg;
nephrotoxicity and
decreased efficacy at
15 mg ⁄ kg
[4,32]
High-dose treatments Highest tolerated doses
in infected animals =
30–50 mg ⁄ kg
Highest tolerated doses
in infected animals =
12–15 mg ⁄ kg
[34,36,41,42,
49,52–54]
Prophylaxis
Localisation in cells
and tissues
Lung epithelial lining fluid;
macrophages of spleen and
liver; renal tubular
epithelium of kidneys
Pulmonary alveolar
macrophages; peripheral
monocytes
[60]
Concentration and
retention in tissues
Concentration ⁄ g tissue: Concentration ⁄ g tissue: [32,61]
Spleen >> liver > lungs =
kidneys
Spleen >> liver > lungs >
kidneys
Retention over 2 weeks:
Liver ›; kidneys M;
spleen ﬂ; lungs ﬂ
Prophylaxis for
pulmonary aspergillosis
Efficacy with multiple
aerosol dosing or
intravenous dosing
Efficacy with multiple
aerosol dosing; not with
intravenous dosing
[63–69]
Prophylaxis for systemic
candidosis
Efficacy with single or
multiple intravenous
dosing
[61,70]
Prophylaxis for systemic
fusariosis
Multiple intravenous dosing
reduced tissue fungal
burden
Multiple intravenous dosing
did not reduce tissue
fungal burden
[44]
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[5,6]. ABLC is composed of ribbon-like structures
with particle sizes between 1600 nm and
11 000 nm and a 1:1 molar ratio of AMB ⁄phos-
pholipid (dimyristoyl phosphatidylcholine and
dimyristoyl phosphatidylglycerol mixture) [7].
ABCD is a complex of AMB and cholesteryl sulfate
in a 1:1 molar ratio that forms thin discoid
structures (diameter 122 ± 20 nm) [8].
Plasma pharmacokinetics
The plasma pharmacokinetics of the three AMB
lipid formulations have been studied extensively
[9–11]. Both ABLC and ABCD are rapidly cleared
from the bloodstream and taken up primarily by
tissues of the reticulo-endothelial system, with
peak plasma levels not exceeding 5 mg ⁄L when
given at therapeutic doses (1–10 mg ⁄kg) [10,12].
In contrast, AmBi at similar doses produces peak
plasma levels that are 25–200 times greater than
those of ABLC and ABCD [13]. Despite these
differences in pharmacokinetics, the efficacies of
the different formulations at doses of 1–10 mg ⁄ kg
are similar in animal models, but at higher doses,
toxicity differences, as discussed below, markedly
alter their therapeutic indices.
Toxicity
As a measure of in-vitro toxicity, attenuation of
red blood cell (RBC) lysis has been studied with
each of the lipid formulations of AMB. Although
Table 1. Continued
Characteristic AmBisome Abelcet References
Prophylaxis
for systemic
histoplasmosis
Efficacy with single intravenous
dosing
[70]
Combination treatment
Zygomycosis Enhanced efficacy with AmBi plus
micafungin
Enhanced efficacy with
ABLC plus caspofungin
[83,89]
Central nervous
system aspergillosis
AmBi plus caspofungin or
micafungin trended to enhanced
survival over monotherapies
ABLC plus
caspofungin equal to ABLC alone,
reduced CFU in brain and
kidneys and enhanced
survival
[84,85]
AmBi plus VCZ enhanced survival
over monotherapies
Systemic aspergillosis VCZ plus AmBi = VCZ, reduced
fungal burden and enhanced
survival vs. AmBi monotherapy
[86,87], Constable
et al., abstract:
3rd AAA, Miami,
FL, 2008Micafungin plus AmBi = micafungin
or AmBi enhanced survival: only
AmBi before micafungin reduced
CFU in spleen
Only micafungin plus AmBi
reduced both fungal burden and
enhanced survival in Aspergillus
flavus infection
Candidosis Sequential and concomitant
therapy with AmBi and
caspofungin reduced CFU vs.
monotherapies in Candida glabrata
infection
[88]
Concomitant therapy with AmBi
and micafungin reduced CFU vs.
monotherapies in C. glabrata
infection
Scedosporiosis AmBi plus caspofungin = AmBi or
caspofungin, enhanced survival;
AmBi plus caspofungin = AmBi,
reduced CFU in kidneys
[90]
AMB, amphotericin B; VCZ, voriconazole.
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specific conditions vary, all of the AMB lipid
formulations were found to be less haemolytic
than AMB [5,8,14]. However, potassium leakage
from RBCs is a more sensitive in-vitro assay of
RBC stability than haemolysis, with potassium
leakage occurring at concentrations of AMB 1 ⁄ 100
of that needed for haemolysis [15]. Jensen et al.
[16] showed distinct differences in the disruptive
effects of the AMB lipid formulations on RBC
membranes using a potassium leakage assay.
When compared to AMB, the drug concentration
needed to cause a 50% release of potassium
(K50) was approximately three, five and 1000
times higher for ABCD, ABLC and AmBi, respec-
tively.
The in-vivo toxicity of the AMB lipid formula-
tions has been evaluated in several animal spe-
cies, particularly mice and rats. In mice, the single
intravenous dose of AMB, ABCD, ABLC or AmBi
that caused death of 50% of the animals (i.e.,
LD5O) was 2–3 mg ⁄ kg for AMB [17,18], 36–
38 mg ⁄ kg for ABCD [8], c. 40 mg ⁄ kg for ABLC
[14], and c. 175 mg ⁄ kg for AmBi [17]. Multiple-
dose toxicity effects have paralleled the toxicity
patterns of single-dose treatment. Multiple dosing
with ABCD in rats was well-tolerated for up to
14 days at a dose of 5 mg ⁄kg [19] but in dogs, at
0.6–5.0 mg ⁄ kg, mild-to-moderate dose-dependent
renal tubular nephrosis with significantly ele-
vated creatinine blood levels was reported [20].
ABCD was not tolerated at 10 mg ⁄ kg in dogs.
ABLC multidose toxicity testing in rats at doses of
1, 3 or 10 mg ⁄kg showed no overt signs of toxicity
[21], although mild, dose-related impairment of
renal function was observed. AmBi multidose
toxicity in rats showed minimal nephrotoxicity
with doses up to 20 mg ⁄ kg in both females and
males [22]. While females of this particular strain
of rats exhibited severe hepatocellular necrosis in
the 20 mg ⁄ kg treatment group, this hepatotoxicity
had not been observed previously with similar
dosing in another strain of female rats [17]. In
dogs, AmBi was well-tolerated up to 4 mg ⁄ kg,
but at higher doses (8 and 16 mg ⁄kg), most
animals had to be killed early due to weight loss
and renal tubular nephrosis [23]. The results in
these multiple-dose toxicity studies reflect the
relative toxicities of the AMB lipid formulations
in patients, with AmBi being less toxic than either
ABCD or ABLC [24,25]. In the case of ABCD,
acute infusion-related toxicities in patients were
equivalent to those found with AMB [25].
Therefore, this review will focus primarily on
ABLC and AmBi.
In-vitro mode of action
Several mechanisms of action may be involved in
the release of AMB from ABLC to allow it to
interact with fungi. In-vitro studies with ABLC
suggested that host tissue-derived phospholipas-
es played a role in releasing AMB from ABLC
[26], but in another study, incubating ABLC with
plasma resulted in greater than 50% of the AMB
being released directly into the plasma. The
majority of the released drug was not associated
with plasma lipoproteins [27]. Further studies are
needed to elucidate the factors involved in release
of the AMB from the phospholipid complex.
The in-vitro mode of action of AmBi has been
well-characterised using several different micro-
scopic techniques. Freeze–fracture scanning elec-
tron microscopy showed that AmBi or liposomes
without drug bound to the surface of the yeast cell
wall [28,29]. This observation was supported by
fluorescent microscopic examination of yeast cells
incubated with sulforhodamine-containing AmBi
or liposomes without drug. Yeast cells incubated
with sulforhodamine-containing liposomes with-
out drug had red fluorescence only on the surface
of their cell walls, while yeast cells incubated with
sulforhodamine-containing AmBi had red fluo-
rescent dye distributed throughout their cyto-
plasm [28]. The results showed that only AmBi
was breaking down and releasing its contents
following contact with the yeast cells.
Using transmission electron microscopy, yeast
cells or mycelia incubated with AmBi formulated
with a small amount of dipalmitoyl phosphati-
dylethanolamine covalently bound to gold nano-
particles showed gold-labelled lipid localised on
the fungal cell wall surface, present within the
cell wall, bound to the fungal cell membrane and
distributed throughout the damaged cytoplasm
of the fungi. In comparison, gold-labelled lipid
from the liposomes without drug could only be
seen on the surface of the fungal cell wall. The
data suggested that AMB was released from
disrupted AmBi and that this released AMB
damaged the fungal cell-membrane, producing
sufficient alteration of the fungal cell to allow the
liposomes or portions of the disrupted liposomes
to penetrate into the disintegrating cytoplasm
[29].
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IN-VIVO EFFICACY
Efficacy of AMB lipid formulations in animal
infection models
Because fungal infections often originate in the
lungs following inhalation of spores, much of the
preclinical work on the AMB lipid formulations
has focused on testing these drugs in pulmonary
models. Numerous studies on pulmonary asper-
gillosis have demonstrated comparable efficacy
for AmBi, ABCD and ABLC at intravenous doses
of 5–10 mg ⁄ kg, with significantly increased
survival and reductions in fungal lung burden
[30–33]. Clemons and Stevens [34] reported that
AmBi or ABLC [35] could also be used to
effectively treat murine pulmonary blastomyco-
sis at doses of 7.5–20 mg ⁄ kg, and that AmBi at
15–30 mg ⁄kg significantly prolonged survival in
mice with pulmonary paracoccidioidomycosis
[36].
Although the site of initial replication of many
fungi is the lungs, treatment of fungal infections
also requires delivery and retention of the drug at
sites of fungal dissemination such as the brain,
kidneys, liver, and spleen. This is critical, since
diagnosis is often delayed [37] and the fungal
burden within these tissues can be considerable at
the time of initiation of treatment. Fungal infec-
tions in the brain are particularly difficult to treat
because of the inability of drugs to penetrate into
this tissue. Groll et al.[38] determined that signif-
icantly higher levels of AMB as AmBi could be
delivered to the brains of uninfected and infected
rabbits with Candida meningitis as compared to
ABLC or ABCD. In this study, AmBi at 5 mg ⁄ kg
was more effective than ABLC or ABCD in
reducing the Candida burden in the brains. Rabbit
studies of coccidioidal meningitis showed that
15 mg ⁄kg AmBi (3· ⁄week) significantly reduced
the fungal burden in the brain and spinal cord of
infected animals as well as decreasing meningeal
histopathology when compared to daily treat-
ment with oral fluconazole or 1 mg ⁄ kg AMB
(3· ⁄week) [39]. ABLC at 7.5 or 15 mg ⁄ kg was also
significantly more effective than oral fluconazole
in this model but, unlike AmBi, ABLC was not
better than 1 mg ⁄kg AMB [40]. In cryptococcal
meningitis, Albert et al. [41] observed that AmBi,
given at 20 or 30 mg ⁄ kg, completely cleared the
yeast from the brains of 44% and 78% of mice,
respectively, while AMB at 3 mg ⁄ kg did not clear
the infection. In murine diabetic ketoacidotic
mucormycosis, which localises in the brain,
Ibrahim et al. [42] demonstrated significant effi-
cacy of AmBi at 15 mg ⁄ kg (7.5 mg ⁄kg twice-
daily) as compared to untreated controls. In
addition, AmBi was recently reported to be more
effective than comparable dosing with ABLC in
the treatment of murine diabetic mucormycosis,
although both formulations were equally effective
in increasing survival of neutropenic mice with
mucormycosis when compared to controls. Fur-
thermore, ABLC was less effective at reducing
brain fungal burden in both mucormycosis mod-
els [43]. In systemic murine aspergillosis, 4 mg ⁄ kg
AmBi, unlike ABLC and ABCD, was as effica-
cious as 0.8 mg ⁄ kg AMB in reducing the fungal
brain burden [44], and in a murine fusariosis
model, AmBi at 15 mg ⁄ kg significantly reduced
the fungal brain burden as compared to controls
[45].
Significant reductions of fungal burden in other
organs (kidneys, liver, spleen) have been reported
in several infection models following treatment
with AMB lipid formulations (i.e., candidosis [46–
48], aspergillosis [30,49], and fusariosis [50]) and
dissemination to the liver and spleen was pre-
vented or significantly reduced (p <0.01) in a rat
pulmonary aspergillosis model following treat-
ment with 1 or 10 mg ⁄kg AmBi [51]. Since AMB
lipid formulations are readily taken up by mac-
rophages in the liver and spleen, these drugs have
also been successfully used to treat macrophage
infections such as histoplasmosis [49,52] and
leishmaniasis [53–55].
Influence of concentration and tissue
localisation on antifungal drug efficacy
Andes et al. [56] examined the relationship be-
tween serum pharmacokinetics and tissue concen-
trations of AMB, AmBi and ABLC in a murine
systemic candidosis model. On a mg ⁄ kg basis,
AMB was four- to eight-fold more potent than
AmBi or ABLC, but had higher kidney exposure
than either lipid formulation. Although ABLC
levels in the lungs and liver were higher than those
of AmBi, both lipid formulations had the same
antifungal activity against systemic candidosis as
measured by CFU reduction in the kidneys, lungs,
spleen and liver. Similarly, Olson et al. [32]
reported that although significantly more drug
was detected in the lungs of animals treated with
15 mg ⁄ kg ABLC as compared to AmBi, CFU
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reduction of Aspergillus fumigatus in the lungs was
the same for both drugs. In the latter study, the
comparative tissue concentrations of AmBi and
ABLC 24 h after the third dose of 15 mg ⁄ kg were
as follows: for ABLC, spleen (488 lg ⁄g) > liver
(142 lg ⁄ g) > lung (37.2 lg ⁄ g) > kidney (10.7
lg ⁄g); for AmBi, spleen (268 lg ⁄g) > liver
(97 lg ⁄ g) > lung (14.7 lg ⁄ g) > kidney (14.5 lg ⁄ g).
One possible explanation for the AmBi efficacy
in these models may be related to its localisation
at infection sites in host tissues. In one study [28],
mice were infected with Candida albicans and
given sulforhodamine-labelled AmBi or sulfo-
rhodamine-labelled liposomes without drug.
Sequential sections of infected kidneys stained
with Gomori methanamine silver to visualise
Candida or unstained to detect the fluorescent
liposomes showed that those areas that contained
pseudohyphae and yeast cells fluoresced red
whether they were treated with sulforhodamine-
labelled AmBi or non-drug-containing liposomes.
The results demonstrated that the liposomes with
or without drug localised at the sites of fungal
infection in the kidneys. Takemoto et al. [57] did a
similar experiment with sulforhodamine-labelled
AmBi administered to mice with a pulmonary
A. fumigatus infection. These investigators also
demonstrated localisation of the fluorescent lipo-
somes at the sites of fungal infection, which in this
case was the lungs. These in-vivo observations
support the in-vitro AmBi studies discussed
above that showed fluorescent or gold-labelled
liposomes with or without drug binding to the
fungal cell wall [28,29].
DRUG TOXICITY AND ITS
RELATIONSHIP TO ANTIFUNGAL
EFFICACY
As mentioned above, clinical studies have shown
that AmBi is the least toxic AMB lipid formulation
[24,25]. In a dose-escalating study by Walsh et al.
[58], repeated dosing of up to 15 mg ⁄ kg AmBi
was well-tolerated by patients, and when given
with other nephrotoxic drugs, such as cyclospor-
ine, AmBi did not significantly increase nephro-
toxicity [59].
These clinical observations have been sup-
ported by some preclinical studies and have
important consequences for drug efficacy
[4,17,32]. In murine pulmonary aspergillosis,
serum blood urea nitrogen levels in cyclophos-
phamide-immunosuppressed A. fumigatus-infected
mice treated with 15 or 20 mg ⁄ kg AmBi or ABLC
were significantly elevated in ABLC-treated mice
as compared to 5% dextrose- or AmBi-treated
mice [32]. Histological evaluation of the tissues of
these infected mice demonstrated that the kidneys
were normal in 5% dextrose- or AmBi-treated
mice, while there was significant acute tubular
necrosis in the ABLC-treated animals. Although
the reduction in fungal lung burden was compa-
rable in mice given 15 mg ⁄ kg AmBi or ABLC,
significantly improved survival rates as compared
to controls was seen only in animals given AmBi.
This difference in efficacy was probably related to
the increased renal toxicity of ABLC at the high
doses. In a triamcinolone-immunosuppressed
pulmonary aspergillosis model [4], there was a
significant elevation in both blood urea nitrogen
and creatinine in animals given 7.5 mg ⁄ kg Anfo-
gen, a recently developed liposomal preparation
of AMB, while these levels were normal in
mice treated with 7.5 or 15 mg ⁄kg AmBi. Histo-
pathological examination of the kidneys from
the AmBi-treated mice again showed no evi-
dence of severe, acute tubular necrosis, while
significant acute tubular necrosis was detected in
animals given 7.5 mg ⁄kg Anfogen. At AmBi
doses of 7.5 and 15 mg ⁄ kg, AmBi was less toxic
and more efficacious (based on survival rates,
CFU reduction and weight loss) than 7.5 mg ⁄ kg
Anfogen.
The markedly reduced nephrotoxicity of AmBi
as compared to other AMB lipid formulations has
led to its being tested at doses ‡10 mg ⁄ kg in
several animal models. Intermittent AmBi treat-
ment of C. albicans-infected mice (20 mg ⁄ kg,
3· ⁄week) resulted in clearance of the infection
from the kidneys after 5 weeks of treatment [60].
In difficult-to-treat animal models, such as muco-
rmycosis [42], paracoccidioidomycosis [36], blas-
tomycosis [34], meningeal cryptococcosis [41],
fusariosis [50], and leishmaniasis [53–55],
repeated treatment with doses of AmBi ranging
from 10 to as high as 50 mg ⁄ kg were well-
tolerated and efficacious in significantly decreas-
ing the fungal or parasitic burden in the target
organs and ⁄ or increasing survival rates. Taken
together, these results indicate that in these severe
infection models, animals could be treated effec-
tively with ‡10 mg ⁄ kg doses of AmBi, because the
drug’s antimicrobial effects were not compro-
mised by its toxicity.
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PROPHYLACTIC TREATMENT
Drug concentration in uninfected cells and
tissues
Although AmBi was initially developed for
therapeutic use, recent preclinical studies have
indicated that AmBi is retained in the cells and
tissues for extended periods of time, supporting
the clinical observation that it can be used
prophylactically in high-risk patients [61]. At
the cellular level, there have been a couple of
studies on the localisation of different AMB
formulations in host cells. Groll et al. [62], using
an HPLC analytical method, investigated the
accumulation of AMB in the lung tissue, pul-
monary alveolar macrophages, lung epithelial
lining fluid and peripheral blood monocytes of
rabbits following treatment with AMB, ABCD,
ABLC or AmBi. They determined that 24 h after
eight daily doses (total dose, 8 mg ⁄ kg for AMB,
and 40 mg ⁄ kg for ABCD, ABLC, or AmBi),
ABLC produced the highest accumulation in
the lung tissue, pulmonary alveolar macrophag-
es and peripheral blood monocytes, while AmBi
achieved the highest concentrations in the lung
epithelial lining fluid. Smith et al. [18], using an
immunohistochemical staining technique with
anti-AMB antibodies, examined the localisation
of AMB within the cells of the kidneys, liver and
spleen of mice following AmBi treatment (total
dose 225 mg ⁄ kg). Three or seven days following
treatment, AMB could be detected as granular
cytoplasmic staining in the renal tubular epithe-
lium, primarily in the convoluted tubules, but
was not detected in the glomeruli. In the liver
and spleen, the AMB localised primarily within
macrophages, i.e., Kupffer cells of the liver and
red pulp macrophages of the spleen. This same
group also studied the retention of AmBi in
different tissues [18]. Using a quantitative AMB
bioassay, AmBi levels in the lungs, kidneys,
liver and spleen were evaluated in uninfected
mice over a period of either 2 days or 2 weeks
post-treatment. After a total dose of 225 mg ⁄ kg
AmBi (15 mg ⁄ kg, 3· ⁄week for 5 weeks), AMB
levels in the lungs, spleen and liver 2 days post-
treatment did not decrease, although levels did
decrease significantly in the kidneys over this
same time period. In comparison, between
weeks 1 and 2 post-treatment, kidney AMB
levels did not decrease, while levels in the lungs
and spleen decreased significantly and drug
concentrations increased in the liver. In this
same study, the investigators reported that
therapeutic levels of AMB from AmBi were
present in the kidneys and spleens 3 and
6 weeks following treatment with a total dose
of 60 mg ⁄kg AmBi.
Prophylactic animal studies
With preclinical reports of therapeutic AmBi
levels remaining in target tissues for several
weeks post-treatment [18] and continued reduc-
tions in fungal burden following cessation of
AmBi treatment [41,63,64], prophylactic studies
with AMB lipid formulations have been done
using different animal models. In a rat aspergil-
losis model, Cicogna et al. [65] reported that
prophylactic aerosol ABLC provided higher, pro-
longed lung levels of AMB than aerosol AMB,
and significantly prolonged survival in pulmon-
ary aspergillosis as compared to controls. Simi-
larly, AmBi delivered as a prophylactic aerosol
significantly increased survival rates of mice
intranasally infected with A. fumigatus [66], as
well as mice with pulmonary cryptococcosis [67].
However, Ruijgrok et al. [68] found that although
aerosol AmBi or aerosol AMB prolonged survival
in a rat pulmonary aspergillosis model, neither
aerosol treatment prevented dissemination of the
lung infection to other organs. Consistent with
these findings, the same investigators reported
that aerosolised AmBi or AMB produced high
levels of drug in the lungs, but low systemic drug
exposure [69].
The studies with aerosolised compounds
suggest that intravenous delivery of AMB lipid
formulations may provide more effective prophy-
laxis for systemic protection than aerosol delivery,
and this has been substantiated by some investi-
gators. Spellberg et al. [45] compared systemic
intravenous prophylaxis with AMB, AmBi and
ABLC in a murine fusariosis model. Only AmBi
significantly decreased the fungal load in kidneys
and brain, although no treatment provided any
significant survival advantage. In a murine pul-
monary aspergillosis model, it was found that
only intravenous AmBi but not ABLC, given at )2
and )4 days prior to challenge, significantly
improved survival and reduced pulmonary fun-
gal burden compared to placebo [70]. In a hae-
matopoetic transplant model of murine
pulmonary aspergillosis, Bitmansour and Brown
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[71] reported that intravenous AmBi prophylaxis
prior to intravenous AmBi therapy significantly
improved survival as compared to intravenous
AmBi therapy alone. In other prophylactic studies
of systemic candidosis and histoplasmosis, Garcia
et al. [72] showed that AmBi, as a single intrave-
nous prophylactic dose of 1, 5, 10, or 20 mg ⁄ kg,
given 7 days before fungal challenge with C. albi-
cans or Histoplasma capsulatum, significantly re-
duced CFU in the Candida-infected kidneys and in
the Histoplasma-infected spleens. When the time
between prophylactic AmBi treatment (total
dose 60 mg ⁄ kg) and C. albicans challenge was
extended to 3 or 6 weeks, other investigators
reported that there was a significant reduction in
CFU in the kidneys [18]. They also reported that
intravenous AmBi prophylaxis with a total dose
of 15 or 30 mg ⁄ kg 1 day prior to challenge with
Candida glabrata resulted in a significant reduction
in kidney fungal burden.
COMBINATION THERAPY
In addition to exploring prophylactic use of the
AMB lipid formulations, there has been renewed
interest in combining AMB formulations with
other antifungal drugs, as a result of the intro-
duction of echinocandins, a new class of antifun-
gal drugs that target b-glucan synthase, which is
needed for cell-wall formation [73], and the
approval of triazoles with expanded spectra of
activity [74]. There are no published randomised,
double-blind, prospective clinical trial reports of
combination treatments using these newer agents
with AMB, although numerous clinical case
reports in salvage settings suggest some im-
proved efficacy with this combination approach
[75]. To obtain additional information about
which combinations might prove most effective
in patients, investigators have begun using pre-
clinical combination studies to gain additional
insight into this area.
Preclinical studies using AMB have shown that
the combination of AMB with lipophilic azoles
such as ketaconazole and itraconazole antagonis-
es the antifungal effects of AMB, while the
hydrophilic azoles, such as fluconazole, are not
antagonistic when used with AMB [76]. In studies
summarised by Steinbach et al. [77], the combina-
tion of AMB and itraconazole produced indiffer-
ent results. In contrast, there are several studies
that have shown improved efficacy with the
combination of AMB and an echinocandin. Exam-
ples of this include caspofungin and AMB for the
treatment of murine systemic Candida parapsilosis
infection [78], caspofungin and AMB [79], or
micafungin and AMB [80] for the treatment of
murine systemic C. glabrata infection. Improved
efficacy has also been reported in several asper-
gillosis models, including micafungin and AMB
for pulmonary aspergillosis in chronic granulo-
matous disease mice [81], and caspofungin plus
AMB or AMB ⁄ intralipid for murine systemic
aspergillosis [82]. In less common infections, such
as coccidioidomycosis, AMB plus caspofungin
prolonged survival and reduced spleen and liver
fungal burdens in treated mice as compared to
controls [83], and in trichosporonosis, the combi-
nation of AMB with micafungin was more effec-
tive at prolonging survival and reducing the
kidney fungal burden than either agent alone
[84]. In contrast, Clemons and Stevens [85]
reported no synergistic or antagonistic activity
of micafungin and AMB in immunosuppressed
DBA ⁄ 2 mice given a pulmonary challenge with
A. fumigatus, and activity was neither increased
nor decreased when voriconazole and AMB were
used to treat pulmonary aspergillosis in guinea-
pigs [86].
Combination preclinical studies using ABLC or
AmBi also suggest better efficacy with certain
combination treatments, although it depends
upon the animal model and the drug. The
combination of caspofungin and ABLC in dis-
seminated zygomycosis in diabetic ketoacidotic
mice [87] improved survival rates, but not organ
clearance, when compared to ABLC alone, but in
murine central nervous system aspergillosis [88],
ABLC plus caspofungin therapy was comparable
to ABLC alone. With AmBi, Clemons et al. [89]
reported that suboptimal doses of AmBi with
voriconazole in murine central nervous system
aspergillosis were significantly more efficacious
in terms of both survival and reduction of tissue
fungal burden than was either drug alone. Sim-
ilarly, voriconazole given with AmBi to treat
invasive systemic aspergillosis in a guinea-pig
model was most effective at reducing tissue
fungal burden, sterilising tissues and reducing
mortality [90]. In contrast, the combination of
ravuconazole and AmBi produced antagonistic
effects in a rabbit pulmonary aspergillosis model
[91]. In a systemic murine aspergillosis model of
A. fumigatus, Graybill et al. [92] reported limited
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additive effects of AmBi and micafungin, with
significantly reduced fungal burden in the
spleens only when AmBi was given before
micafungin. In murine systemic aspergillosis
caused by Aspergillus flavus, increased survival
rates were observed with caspofungin or mica-
fungin monotherapy or AmBi plus echinocandin
therapy. However, only AmBi monotherapy or
AmBi plus echinocandin therapy significantly
reduced the fungal burden in the kidneys, livers
and spleens (Constable D., et al., 3rd Advances
Against Aspergillosis, Miami, FL, USA, 2008).
With Candida infections, micafungin or caspofun-
gin used sequentially or concurrently with AmBi
was significantly more effective than monothera-
py in reducing and clearing the yeast from the
kidneys of C. glabrata-infected mice [93], and the
combination of AmBi with micafungin or anidu-
lafungin significantly improved survival and
reduced kidney fungal burden as compared to
monotherapies in mice with disseminated zygo-
mycosis [94]. And finally, using a murine scedos-
poriosis model, Bocanegra et al. [95] showed that
the combination of AmBi and caspofungin or
AmBi alone had comparable efficacy.
CONCLUSION
This review has highlighted the more recent
preclinical work using AMB lipid formulations,
with a focus on AmBi and ABLC, to describe their
similarities and differences and how they might
be used in the future to treat life-threatening
fungal infections. Although their in-vivo efficacies
at doses of 5 mg ⁄ kg in animal models are similar,
the differences in their toxicity have resulted in
marked variations in therapeutic indices. Because
of the significantly lower toxicity for AmBi and its
better brain penetration as compared to other
AMB lipid formulations, investigators have been
able to use AmBi safely and repeatedly at high
doses for treating brain and other difficult-to-treat
infections, such as fusariosis and zygomycosis.
ABLC accumulates in the lungs at higher concen-
trations than AmBi, but both drugs have compa-
rable efficacy in treating pulmonary infections,
and this may be related to the unique targeting of
AmBi to sites of fungal infection in the tissues.
Retention of these agents within the target tissues
has increased interest for their prophylactic use,
and with the introduction of new antifungal
drugs, there have been an increasing number of
preclinical reports of combination therapy with
AmBi or ABLC. In the future, there will continue
to be an important clinical role for the AMB lipid
formulations in the treatment of invasive fungal
infections.
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